NLRP3 and ischemia reperfusion injury: MCC950 inhibits canonical and noncanonical NLRP3 inflammasome activation by blocking the ATPase domain of NLRP3 (11), exerting protective effects in models of AKI, such as ischemia-reperfusion injury (IRI) and sepsis-induced AKI (12–14).